Increasingly, people with relapsing-remitting multiple sclerosis (RRMS) are switched to highly effective disease-modifying therapies (DMTs) such as ocrelizumab.
Objective:
To determine predictors of relapse and disability progression when switching from another DMT to ocrelizumab.
Methods:
Patients with RRMS who switched to ocrelizumab were identified from the MSBase Registry and grouped by prior disease-modifying therapy (pDMT; interferon-β/glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod or natalizumab) and washout duration (<1 month, 1–2 months or 2–6 months). Survival analyses including multivariable Cox proportional hazard regression models were used to identify predictors of on-ocrelizumab relapse within 1 year, and 6-month confirmed disability progression (CDP).
Results:
After adjustment, relapse hazard when switching from fingolimod was greater than other pDMTs, but only in the first 3 months of ocrelizumab therapy (hazard ratio (HR) = 3.98, 95% confidence interval (CI) = 1.57–11.11, p = 0.004). The adjusted hazard for CDP was significantly higher with longer washout (2–6 m compared to <1 m: HR = 9.57, 95% CI = 1.92–47.64, p = 0.006).
Conclusion:
The risk of disability worsening during switch to ocrelizumab is reduced by short treatment gaps. Patients who cease fingolimod are at heightened relapse risk in the first 3 months on ocrelizumab. Prospective evaluation of strategies such as washout reduction may help optimise this switch.
MerkelBButzkuevenHTraboulseeAL, et al. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review. Autoimmun Rev2017; 16(6): 658–665.
3.
Rae-GrantADayGSMarrieRA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology2018; 90: 777–788.
4.
ChalmerTAKalincikTLaursenB, et al. Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy. J Neurol2019; 266(2): 306–315.
5.
JokubaitisVGLiVKalincikT, et al. Fingolimod after natalizumab and the risk of short-term relapse. Neurology2014; 82: 1204–1211.
6.
KapposLRadueE-WComiG, et al. Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS. Neurology2015; 85: 29–39.
7.
CohanSLMosesHCalkwoodJ, et al. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY). Mult Scler Relat Disord2018; 22: 27–34.
8.
AlcaláCGascónFPérez-MirallesF, et al. Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing–remitting multiple sclerosis is effective and safe. J Neurol2019; 266: 726–734.
9.
EllwardtERolfesLKleinJ, et al. Ocrelizumab initiation in patients with MS: A multicenter observational study. Neurol Neuroimmunol Neuroinflamm2020; 7(4): e719.
10.
SignorielloELusGBonavitaS, et al. Switch from sequestering to anti-CD20 depleting treatment: Disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy. Mult Scler. Epub ahead of print 15 April 2021. DOI: 10.1177/13524585211005657.
11.
BarryBErwinAAStevensJ, et al. Fingolimod rebound: A review of the clinical experience and management considerations. Neurol Ther2019; 8(2): 241–250.
12.
HolmøyTTorkildsenØZarnovickyS. Extensive multiple sclerosis reactivation after switching from fingolimod to rituximab. Case Rep Neurol Med2018; 2018: 5190794.
13.
SchmidtSSchultenT. Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: Report of two cases. Ther Adv Neurol Disord2019; 12: 1756286419846818.
14.
Boudot de la MotteMLouapreCPapeixC, et al. Challenges of switching towards anti-CD20 monoclonal antibodies in RR-MS: A monocentric study. Mult Scler Relat Disord2021; 52: 102981.
15.
LevinSNEzumaCLevineL, et al. Switching from natalizumab to ocrelizumab in patients with multiple sclerosis. Mult Scler2020; 26(14): 1964–1965.
16.
AlpingPFrisellTNovakovaL, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients: Rituximab vs fingolimod. Ann Neurol2016; 79: 950–958.
17.
ButzkuevenHChapmanJCristianoE, et al. MSBase: An international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler2006; 12(6): 769–774.
18.
ThompsonAJBanwellBLBarkhofF, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018; 17: 162–173.
19.
HealyBCEnglerDGlanzB, et al. Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis. Mult Scler Int2013; 2013: 189624.
20.
BarkhofFKapposLWolinskyJS, et al. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019; 93: e1778–e1786.
21.
BrinkmannV. FTY720 (fingolimod) in multiple sclerosis: Therapeutic effects in the immune and the central nervous system. Br J Pharmacol2009; 158(5): 1173–1182.
22.
FrancisGKapposLO’ConnorP, et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler2014; 20: 471–480.
23.
HenaultDGalleguillosLMooreC, et al. Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis. Neurology2013; 81: 1768–1772.
24.
CavoneLFeliciRLapucciA, et al. Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound. Brain Behav Immun2015; 50: 78–86.
25.
HatcherSEWaubantENourbakhshB, et al. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol2016; 73: 790–794.
26.
MancinelliCRScarpazzaCCordioliC, et al. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab. Mult Scler2021; 27(5): 790–794.
27.
AmatoMPFondericoMPortaccioE, et al. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain2020; 143: 3013–3024.
28.
Grand’MaisonFYeungMMorrowSA, et al. Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: Perspectives and approaches. Neural Regen Res2018; 13(11): 1871–1874.
29.
ZanghìAGalloAAvolioC, et al. Exit strategies in natalizumab-treated RRMS at high risk of progressive multifocal leukoencephalopathy: A multicentre comparison study. Neurotherapeutics2021; 18(2): 1166–1174.
30.
WillisMPearsonOIllesZ, et al. An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2017; 4(2): e320.
31.
GenbergHHanssonAWernersonA, et al. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant2006; 6(10): 2418–2428.
32.
CiocAMVanderwerfSMPetersonBA, et al. Rituximab-induced changes in hematolymphoid tissues found at autopsy. Am J Clin Pathol2008; 130(4): 604–612.
33.
GelzeichterT. Reduction and reconstitution of B-cells in peripheral blood and lymphoid issues in cynomolgus monkeys following administration of ocrelizumab. Mult Scler2014; 20: 285–496.
34.
SchröderCAzimzadehAMWuG, et al. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol2003; 12(1): 19–28.
35.
GibianskyEPetryCMercierF, et al. Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. Br J Clin Pharmacol2021; 87: 2511–2520.
